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ABSTRACT PCR was used to clone isolates of the human
immunodeficiency virus type 1 (HIV-1) nef gene directly from
peripheral blood leukocytes of HIIV-1-infected individuals. A
transient expression system with human CEM T ceils was used
to assess the effect of nefon CD4 antigen expression on the ceHl
surface. We show that CD4 down-regulation is a frequent
property of primary HIV-1 nefafleles. Mutations in conserved
amino acid motifs of Nef disrupted CD4 down-regulation. Our
observations strongly suggest that CD4 down-regulation re-
flects a conserved function of nef, which is selected in vivo in
human HIV-1 infection. Methodology described here provides
quantitative assays to establish whether alterations in nef
correlate with the dynamics of disease progression in human
AIDS.
nefgenes of human immunodeficiency virus type 1 and type
2 (HIV-1 and HIV-2) and simian immunodeficiency virus
encode related small cytoplasmic proteins (1, 2). Data from
in vivo experiments in rhesus monkeys indicate that nefis an
important pathogenic determinant of these viruses and that
nefis essential for high viral load and disease induction in this
primate model for human AIDS (3).
In contrast to the data from in vivo studies, nef is not
required for viral replication in primary T cells nor estab-
lished T-cell lines under the commonly used in vitro condi-
tions (3-5), and nef open reading frames (ORFs) from viral
isolates that have been propagated in vitro frequently encode
prematurely terminated and, hence, most likely nonfunc-
tional Nef proteins (6, 7). So far no consistent function has
been ascribed to nefthrough the in vitro studies. The initial
reports of a negative effect of nefon viral replication (4, 5, 8)
and expression (9, 10) were either not confirmed (11, 12) or
contradicted (13) by more recent studies. A block to inter-
leukin 2 gene induction was observed in stable cell lines
expressing some, but not other, HIV-1 nef alleles (14). Also,
it was reported that nef from the HIV-1 SF2 isolate down-
modulates CD4 antigen on the cell surface (15), but these
observations were not confirmed by other studies (16, 17).
We have reported previously that Nefprotein from the HIV-1
NL43 isolate, but not from the HIV-1 HxB3 isolate, down-
regulated expression of CD4 antigen in human and murine T
cells (18). HIV-1 NL43 Nef had a dramatic effect on devel-
opment and activation of CD4+ T cells when expressed in
transgenic mice, and this correlated with CD4 down-
regulation on thymic T cells (18).
The apparently contrasting results from in vitro experi-
ments frequently reflect genetic variation among commonly
studied nef alleles (13, 14, 18), and this variation may result
from the absence of selection for nef function upon in vitro
propagation of cloned viruses. Therefore, in an attempt to
circumvent limitations resulting from lack of genetic selec-
tion for nefunder the in vitro conditions, we isolated a large
number of HIV-1 nef alleles directly from two patients
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
infected with HIV-1. In this report we present results of the
analysis of CD4 down-regulation by these primary HIV-1 nef
alleles.
MATERIALS AND METHODS
PCR Amplification of Primary HIV-1 nef Isolates. DNA
isolated from peripheral blood leukocytes of asymptomatic,
HIV-1-positive patients SK1 and SK4 (W. Phares, P. Baron,
J. Gold, and W. Herr, personal communication) and Nef-1
(GCCGAATTCTAGCAGTAGCTGAGGGGACAGATAG)
and HU3-3 (AGGCAAGCTTTATTGAGG) primers, which
hybridize to HIV-1 sequences; positions 8410-8935 and
375-352 in the North American consensus sequence (1),
respectively, were provided by W. Phares and W. Herr (Cold
Spring Harbor Laboratory). PCR (19) was done with dena-
turation at 94°C (40 sec), hybridizing at 62°C (40 sec), and
extension at 72°C (3 min) for 25 cycles in the conditions
recommended by the manufacturer (Boehringer Mannheim).
Subsequently, amplification reactions were diluted 200-fold
with the reaction buffer and the second round of PCR with
NEFSEX and NEF3-Mlu (18) primers, which introduce the
Xba I and Mlu I cloning sites flanking nefORF, was done for
another 25 cycles, as described above. Amplified 0.7-kb
fragments that compose the Nef ORF were isolated by
PAGE, digested with Xba I and Mlu I, and subcloned into
Xba I- and Mlu I-cut CD3 TEX expression vector (18).
Analysis of Primary HIV-1 nef Isolates. The nucleotide
sequence ofNA and NB clones was determined, as described
(20). Oligonucleotide-directed mutagenesis was done with
the NA7 nef, subcloned into the pBS vector (Stratagene), as
described (21). All mutations were verified byDNA sequence
analysis. Electroporation, flow cytometry analysis of CEM
E5 cells (22), and immunoblot analysis of Nef expression
were done as described (18).
RESULTS
Cloning of Primary HIV-1 nef Isolates. The nef gene was
isolated fromDNA isolated from peripheral blood leukocytes
oftwo asymptomatic HIV-1-infected patients, SK1 and SK4,
by two rounds ofPCR (see Materials andMethods for further
details). Amplified fragments were cloned directly into the
CD3l3 T-cell-specific expression vector, and clones contain-
ing nef inserts were identified by PCR. The two groups of
clones derived from SK1 and SK4 patients are further
referred to as CD3 NA (18 clones) and CD3 NB (3 clones),
respectively. The NA and NB clones were used in two types
of assays. First, to identify functional Nef ORFs, individual
clones were transiently expressed in CEM T cells, and
protein extracts were analyzed by immunoblotting. Subse-
quently, all clones that directed detectable expression of Nef
protein were analyzed for CD4 down-regulation.
Abbreviations: ORF, open reading frame; HIV-1, human immuno-
deficiency virus type 1.
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Identification of Functional HIV-1 nef ORFs. To identify
CD3 NA and NB clones that direct synthesis of the 27-kDa
Nef polypeptide individual CD3 NA and NB clones were
introduced into human CD4+ CEM T cells, and protein
extracts prepared from transfected cells were analyzed by
immunoblotting with a rabbit anti-Nef serum (18). Alto-
gether, 15 out of 18 NA, and 3 out of 3 NB clones tested
directed readily detectable expression of Nef proteins, and a
representative result from this analysis is shown in Fig. 1.
Clones NA1, -3, -4, -5, -6, -8, and -14 directed expression of
Nef at levels comparable to that of the NL43 and HxB3
proteins, which were used as standards. In contrast, clones
NA1l, -15, and -17 directed significantly lower expression,
suggesting lower stability of proteins encoded by these nef
alleles. The electrophoretic mobility of most of the NA Nef
proteins was indistinguishable from that of the HIV-1 NL43
Nef, except for NA4 Nef, which migrated slightly faster. The
observed variation in Nef expression and electrophoretic
mobility suggested heterogeneity within the NA population
of nef alleles.
CD4 Down-regulation Is a Frequent Property of Primary
HIV-1 nef Isolates. A transient assay in human CD4+ CEM T
cells (18) was used to assess the effect of primary nef alleles
on CD4 antigen expression on the cell surface. As illustrated
in Fig. 2A, transfection with the CD3-LacZ reporter con-
struct, but not with a control CD3 TEX plasmid, resulted in
a high level of ,3galactosidase activity in a large fraction of
electroporated cells ((-galactosidase-positive cells; compare
I and 2), and f3-galactosidase expression had no effect on
CD4 expression on the surface of 3-galactosidase-positive
cells (compare the right and left upper quadrants in 2). As
shown before (18), transfection with the HIV-1 NL43 nef, but
not with HxB3 nef, caused an =50-fold decrease in CD4
staining (4 and 5, respectively).
Results of the analysis of 6 of the 14 CD3 NA clones tested
are shown in Fig. 2A, 6-10, and a compilation of analyses
done with nef isolates from the SKi and SK4 patients is
shown in Fig. 2B. Expression of Nef from all clones derived
from SKi effected a decrease in CD4 antigen expression on
the surface of CEM T cells, although to different extents.
Interestingly, nefalleles from several of these clones, includ-
ing NA3, -7, -10, -13, -14, -18, -11, and -15, were more potent
in CD4 down-regulation than was NL43 nef. The NA1, -5, -6,
-8, and NB1 alleles were as potent as the NL43 Nef. In
contrast, the NA4, NA17, NB5, and NB9 alleles were
exceptional in that they had little effect on surface CD4
expression.
Results from immunoblot analysis (see Fig. 1) indicated
some degree of correlation between the steady-state level of
Nef protein expression and CD4 down-regulation. For ex-
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FIG. 1. Immunoblot analysis of Nef proteins from SK1 nef
alleles. One hundred-microgram aliquots of protein extracts pre-
pared from CEMT cells electroporated with the indicated expression
vectors were separated by SDS/PAGE and immunoblotted with
anti-Nef serum. CEM cells transfected with CD3 HxB3 and NL43
vectors, which direct expression of the HIV-1 HxB3 and N143 Nef
proteins, were used as a positive control. CEM cells electroporated
with CD3 TEX, which contains HIV-1 tat cDNA, provided a
negative control (MOCK). Molecular size ofproteins revealed by this
analysis was estimated by using molecular size standards (kD, kDa;
Amersham).
ample, all Nef alleles that effected CD4 down-regulation also
directed detectable expression of Nef proteins in transiently
transfected CEM T cells. The relatively weak CD4 down-
regulation by NA17 Nef and NB5 and NB9 alleles correlated
with a relatively low steady-state-level expression of corre-
sponding Nef proteins in CEM T cells. Only the NAll Nef
was exceptional in that it had a potent effect on CI4 in spite
of a relatively low steady-state expression. Thus, the rela-
tively weak CD4 down-regulation may, in many cases, reflect
decreased stability of the corresponding Nef proteins. In
contrast, the weak NA4 allele is clearly exceptional because
the steady-state-level expression of NA4 Nef was compara-
ble to that of NL43 Nef protein.
Mutations in Conserved Nef Motifs Disrupt CD4 Down-
regulation. To characterize HIV-1 nef alleles further, the
nucleotide sequence of 14 nef isolates from patient SK1 and
of 3 nef isolates from patient SK4 was determined. The
predicted amino acid sequences of respective Nef proteins
from SK1 segregated into two closely related families (NA
groups I and II), for which consensus sequences are shown
in Fig. 3. Within each of these two groups the amino acid
variation between Nef proteins was <1% (0.9%o and 0.3%
within group I and II proteins, respectively). In contrast,
each of the group I Nef sequences differed from those of
group II at nine diagnostic positions (4.4% divergence). A
total of 19 amino acid substitutions was found among SK1
clones (Fig. 3 and Table 1). The consensus amino acid
sequence derived from SK4 nefisolates differed from that of
SK1 at 35 positions (17% divergence). Seventeen amino acid
differences were found between NB clones (8.3% diver-
gence, see Fig. 3 and Table 1). Table 1 shows that most amino
acid variation involved conservative substitutions and had a
marginal or nondetectable effect on CD4 down-regulation.
Analysis of sequences of the defective NA17 and NA4
proteins revealed two candidate loss-of-function mutations in
NA17 (Val-148 -* Asp and Glu-155 -) Val) and one in NA4
(Asp-36 -) Gly). The comparison of NL43 Nef with the
defective HxB3 Nef identified five additional candidate dis-
abling mutations (Val-33 -* Ala, Glu-65 -+ Lys, Cys-142
Arg, Val-153 -* Leu, and Phe-191 -* Leu, Fig. 3).
To identify amino acid residues associated with loss ofCD4
down-regulation by NA4, NA17, and HxB3 Nefs, mutations
specific to these partially defective genes were transferred
onto the background of the highly active NA7 nef allele. In
an additional experiment the conserved Gly-2 was replaced
with alanine. This mutation disrupts the N-terminal myris-
toylation site conserved in Nef proteins of both human and
simian viruses (1, 23). The effect of these mutations on CD4
down-regulation was quantitated and correlated with the
steady-state expression level of mutant Nef proteins in a
dose-response experiment.
Fig. 4A shows that doses of 0.5 pg of the CD3 NA7
construct effected a decrease in CD4 expression and doses of
5 pug and higher saturated the response. In contrast, three of
the tested mutations reduced down-regulation of surface CD4
by NA7 Nef (Fig. 4). First, mutation that disrupted the
N-terminal myristoylation site in the NA7.1 Nef essentially
abolished CD4 down-regulation at DNA doses below 5 ug,
whereas higher doses of 15 and 50 Ag effected a modest
decrease in CD4 expression on the cell surface. As shown in
Fig. 4B, immunoblot analysis of cytoplasmic extracts pre-
pared from cells transfected with 15 pg and 50 ug of the
wild-type CD3 NA7 or the CD3 NA7.1 constructs revealed
that the steady-state expression level of mutant NA7.1 Nef
was higher than that of NA7 Nef for both these doses
(compare lanes 1 and 2 with 7 and 8, respectively). Thus,
disruption of the conserved N-terminal myristoylation signal
in Nef reduced CD4 down-regulation to a large extent. The
second mutation, Asp-36 -+ Gly (NA7.3 Nef), originally
found in the defective CD3 NA4 clone, decreased CD4
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FIG. 2. Primary HIV-1 Nef iso-
lates down-regulate CD4 in a tran-
2 sient assay. (A) CEM T cells were
100 1000 electroporated with control expres-
sion vectors containing HIV-1 tat
cDNA (CD3 TEX), NL43 nef (CD3
D NL43), HxB3 nef (CD3 HxB3), and
acZ the CD3 LacZ reporter plasmid (CD3
iA14 LacZ) (Upper), or with selected CD3NA clones (Lower). P-Galactosidase12 activity and CD4 antigen expression
on the cell surface were analyzed by
flow cytometry and are shown on the
abscissa and ordinate, respectively,
in the logarithmic scale. Percentage
926 fraction ofcell populations expressing
100 1000 wild-type or reduced levels of CD4
and high or low levels of ,-galacto-
sidase activity are shown in the cor-
ners of each quadrant. (B) Compila-
tion of results from flow cytometry
analyses of nef alleles from patients
CD4 surface SK1 and SK4. Each arrow represents
expression an individual NA or NB nef clone,
(log scale) which is identified by a number be-
low. Each arrow reflects the median
level of CD4 expression on the sur-
face of,-galactosidase-positive CEM
cells transfected with the respective
expression vector. Vertical lines rep-
resent the wild-type (WT)-level CD4
expression on CEM T cells and the
autofluorescence of fluorescein diga-
lactoside-loaded CEM cells that were
not stained for CD4 (CEM not
stained) and are provided as a refer-
ence. CD4 expression on CEM cells
electroporated with the CD3 NL43
and CD3 HxB3 vectors is shown for
comparison. Representative results
from three independent experiments
are shown.
down-regulation by severalfold (Fig. 4A) despite similar
steady-state expression of both mutant NA7.3 and wild-type
NA7 Nefproteins (Fig. 4B, compare lanes 9 and 10 with lanes
1 and 2, respectively). Therefore, the NA7.3 Nef encodes
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stable, but partially inactive, protein. The third mutation was
Cys-122 -* Lys (NA7.17), found in HxB3 Nef. Fig. 4 shows
that a high dose of 50 pg of the mutant CD3 NA7.17 only
marginally affected CD4 expression. Results from immuno-
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FIG. 3. Predicted amino acid sequences ofNA Nefproteins. Consensus amino acid sequences for Nefproteins derived from SK1 (NA clones)
and SK4 patient (NB clones) are shown in the upper line (cons). The consensus sequences for NA group I, group II, and NB Nef proteins are
aligned below. Amino acid sequences of the HIV-1 NL43 and HxB3 Nef proteins are shown for comparison. Dots indicate sequence identity,
and amino acid sequences are shown in the one-letter code. Group I consists of 11 clones (NA1, -3, -5, -6, -7, -8, -10, -11, -13, -15, and -17),
and group II consists of 3 clones (NA4, -14, and -18). Amino acid variation within group I and group II clones is shown in Table 1.
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Table 1. Amino acid substitutions in Nef proteins from
SK1 patient
CD4
Xaa -. Yaa down-
SK1 clone substitution regulation
NA group I
NA3, -7, -10, -13 NA consensus I ++
NAl Val-146 -- Ala + +
NA5 Ser-34 -b Pro + +
NA6 Val-146 Ala + +
Ser-169 Asn + +
NA8 Gly-67 Glu + +
NAll Gly-11lArg ++
NA15 Thr-117 Ala ++
Pro-129 Ser ++
NA17 Val-148 Asp + +
Glu-155 Val+/
NA group II
NA14, -18 NA consensus II + +
NA4 Asp-36 Gly +/ -
NB
NB1 Gln-71 - Trp + +
Gly-106-Arg ++
NB5 Ser-8-Arg ++ (a)
Ala-15 Thr ++
Thr-51iAsn ++
Glu-62 Lys ND
Phe-81 Tyr + +
Gly-83 Ala + +
Tyr-102 His + +
Gln-104 Leu ND
Arg-107 Gln ++
Thr-133 Ile ++
Gln-150 Pro + + (a)
Arg-152 Lys ++ (a)
Cys-163 Ser + +
Ser-188 Arg ++
Val-194 Met ++
NB9 NB consensus +/_
Amino acid differences (Xaa-. Yaa) between sequences predicted
for Nef proteins encoded by individual NA alleles and the consensus
sequences, presented in Fig. 3, are shown. To test the effect of
individual amino acid substitutions on CD4 down-regulation, muta-
tions were transferred onto the background NA7 nefand assayed as
described for Fig. 2B. (a) Amino acid residues shared with NL43
Nef; ND, not determined.
blot analysis revealed a relatively low steady-state expres-
sion directed by 15 and 50 Mg of mutant CD3 NA7.17, when
compared with those directed by the wild-type CD3 NA7
construct (compare lanes 11 and 12 with 1-5, Fig. 4B).
However, the steady-state level of NA7.17 Nef in cells
transfected with 50 ug of this DNA was comparable to that
directed by 5.0 pg of the wild-type CD3 NA7 construct
(compare lane 11 and 3, Fig. 4B), which had a subsaturating
effect on CD4 down-regulation (Fig. 4A). Therefore, the
NA7.17 mutation has a 2-fold effect and affects both the
stability and some function(s) ofNefprotein required for CD4
down-regulation. The remaining four unique amino acid
substitutions found in HxB3 Nef had no effect on CD4
down-regulation when tested on NA7 background (data not
shown).
Finally, we analyzed two amino acid changes found in the
defective NA17 Nef allele (Table 1). The Glu-155 -- Val
substitution had no detectable effect on either stability or
CD4 down-regulation. In contrast, the Val-148 Asp sub-
stitution resulted in a low steady-state expression of the
mutant protein and partial loss ofCD4 down-regulation (data
not shown). Therefore, defective CD4 down-regulation by
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FIG. 4. Mutations in Nef that disrupt CD4 down-regulation. (A)
The effect of selected mutations in NA7 Nefon CD4 down-regulation
was analyzed in a dose-response experiment. CEM cells were
coelectroporated with CD3 LacZ reporter (0.5 pg-5 ug) and different
amounts of the wild-type (CD3 NA7) or mutant (CD3 NA7.1, 7.3,
7.17) expression vectors (0.5, 1.5, 5.0, 15, or 50 Ag, shown on the
abscissa). CD4 expression on the cell surface was determined by flow
cytometric analysis 24 hr later. The median level of CD4 on the
surface of f-galactose-positive cells recorded on the logarithmic
scale is shown on the ordinate. (B) Immunoblot analysis of mutant
Nef proteins. Steady-state expression of wild-type and mutant Nef
proteins from the experiment shown in A was determined by immu-
noblot analysis of 25-pg aliquots of protein extracts prepared from
CEM cells electroporated with the indicated amounts of CD3 NA7
construct (lanes 1-5), control CD3 TEX plasmid (lane 6), or mutant
CD3 NA7.1 (lanes 7 and 8), CD3 NA7.3 (lanes 9 and 10), and CD3
NA7.17 (lanes 11 and 12).
NA17 Nef may result from decreased stability of the mutant
protein.
DISCUSSION
In an attempt to circumvent limitations resulting from lack of
genetic selection for nefunder in vitro growth conditions, we
isolated a large number ofHIV-1 nefalleles directly from two
asymptomatic patients infected with HIV-1. Immunoblot
analyses determined that >80% of nef alleles isolated from
patient SK1 directed synthesis of Nef proteins at levels
comparable with that of the HIV-1 NL43 Nef. These obser-
vations are consistent with the previously observed require-
ment for nef in the natural setting of HIV infection (3) and
strongly suggest that these nefalleles are functional. The low
level of amino acid sequence divergence (4.3%) seen among
14 NA nef isolates was similar to that reported (24). Most
amino acid replacements identified among Nef proteins from
SK1 patients, except for those found in NA4 and NA17 Nef
proteins, represented conservative amino acid substitutions.
Thus, the observed divergence is likely to represent the
preexisting heterogeneity of Nef in vivo in the SK1 patient
rather than errors generated during PCR amplification in
vitro. The two predominant families of NA Nef sequences
observed are consistent with two major HIV-1 quasispecies
Proc. Natl. Acad Sci. USA 90 (1993)
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that evolved in the SK1 patient but may reflect two indepen-
dent infection events.
Evidence from experiments presented here strongly sug-
gests that CD4 down-regulation reflects a conserved, se-
lected in vivo function of nef. (i) Approximately 80%o of all nef
alleles, including all those that directed detectable expression
of Nef protein, down-regulated surface CD4 antigen upon
transient expression in CEM T cells. The observation that the
remaining 20% ofSK1 nefalleles showed no effect on surface
CD4 expression is not contradictory. A similar frequency of
functionally defective alleles (30%) was observed before with
the HIV-1 tat gene, which is essential for the viral life cycle
(25). (ii) Although sequence variation observed among pri-
mary isolates of Nef proteins and the NL43 Nef amounted
altogether to >40 amino acid substitutions, most reflected
conservative changes with little or no detectable effect on
CD4 down-regulation. (iii) CD4 down-regulation was dis-
rupted by nonconservative replacements in amino acid motifs
that are conserved among human and simian Nef proteins.
Specifically, an intact N-terminal myristoylation site, which
is invariantly found in both HIV-1 and HIV-2/simian immu-
nodeficiency virus Nef proteins, was required for full Nef
activity. Moreover, CD4 down-regulation is also disrupted by
a mutation altering the conserved cysteine found in all HIV-1
Nefs in the central domain that is highly conserved between
human and simian Nef proteins (1).
CD4 down-regulation by nef has been observed before in
human and murine T cells stably expressing nef alleles
derived from some (15, 18, 23), but not the other HIV-1
isolates that have been repeatedly passaged in vitro (18). Our
observations indicate that CD4 down-regulation quantita-
tively depends on the level ofNefprotein expression and that
some nefalleles derived from the in vitro established viruses,
or cloned directly from infected patients, encode defective
and/or unstable proteins that are nonfunctional. These two
variables may explain the lack of CD4 down-regulation by
Nef reported by Gama Sosa et al. (16) and Schwartz et al.
(17).
It is well established that dynamics of disease progression
can vary greatly among HIV-infected people. Results from in
vivo experiments in rhesus monkeys indicated that nef is
essential for simian immunodeficiency virus pathogenesis (3)
and nef-deficient simian immunodeficiency virus can protect
infected animals upon subsequent superinfection with the
wild-type virus (26). Methodology described here provides a
quantitative assay to assess nef function in HIV-infected
people and to establish whether alterations in nef are asso-
ciated with differences in disease progression in human
AIDS.
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